KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash & Equivalents (2020 - 2025)

AbCellera Biologics' Cash & Equivalents history spans 6 years, with the latest figure at $83.2 million for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 34.33% year-over-year to $83.2 million, compared with a TTM value of $83.2 million through Sep 2025, down 34.33%, and an annual FY2024 reading of $156.3 million, up 17.26% over the prior year.
  • Cash & Equivalents for Q3 2025 was $83.2 million at AbCellera Biologics, down from $92.4 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $815.6 million in Q2 2022, with the low at $83.2 million in Q3 2025.
  • Average Cash & Equivalents over 5 years is $410.6 million, with a median of $372.0 million recorded in 2022.
  • Year-over-year, Cash & Equivalents soared 39.33% in 2023 and then plummeted 86.21% in 2025.
  • Tracing ABCL's Cash & Equivalents over 5 years: stood at $476.1 million in 2021, then tumbled by 45.33% to $260.3 million in 2022, then crashed by 48.78% to $133.3 million in 2023, then rose by 17.26% to $156.3 million in 2024, then tumbled by 46.8% to $83.2 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Cash & Equivalents are $83.2 million (Q3 2025), $92.4 million (Q2 2025), and $159.3 million (Q1 2025).